Search the database for deliberate release of GM medicinal products
Displaying 1 - 4 of 4
|EU record number
|Company / Sponsor
|A phase 2 study to assess the safety and efficacy of GM Lactococcus lactis for the attenuation of oral mucositis in subjects with cancers of the head and neck
|Biologically contained strain of Lactococcus lactis, genetically modified to secrete human Trefoil Factor 1 (hTFF1).
|Only notified under the "contained use" procedure. Dossier submitted on 21/02/2018.
|Efficacy and safety of bilateral intravitreal injection of GS010: a randomized, double-masked, placebo-controlled trial in subjects affected with G11778A ND4 leber hereditary optic neuropathy for up to one year.
|human wild-type MT-NDA (mitochondrial NADH Dehydrogenase 4)
|Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
|Pfizer, Animal Health Group
|gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)
|Only notified under the "contained use" procedure. Dossier submitted on 02/01/1996.
|Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system
|Sandoz Pharma, LTD
|Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)